Literature DB >> 28351504

Changes in nationwide use of preoperative radiotherapy for rectal cancer after revision of the national colorectal cancer guideline.

L Gietelink1, M W J M Wouters2, C A M Marijnen3, J van Groningen4, N van Leersum5, R G H Beets-Tan6, R A E M Tollenaar4, P J Tanis7.   

Abstract

BACKGROUND: The rate of preoperative radiotherapy (RT) for rectal cancer in the Netherlands has been the highest among European countries. Revision of the national guideline on colorectal cancer, officially published in 2014, specifically focussed on the indication for RT and MRI criteria to evaluate mesorectal lymph nodes. The objective of this study was to evaluate implementation of the revised guideline using a national audit.
METHODS: Data of the Dutch Surgical Colorectal Audit (DSCA) between 2009 and 2014 were used to evaluate RT use and RT regimen for relevant subgroups of cM0 rectal cancer patients, as well as accuracy of pre-operative MRI.
RESULTS: 14,018 patients were included for analysis. Overall RT use in cT1-4N0-2M0 stage ranged from 81.4% to 84.2% between 2009 and 2013, and decreased to 64.4% in 2014. The absolute decrease in RT use from 2013 to 2014 for cT1N0, cT2N0 and cT3N0 stage was 32.8%, 43.5% and 31.6%, respectively. Short course RT with delayed surgery was used as an alternative to chemoradiotherapy up to 2013 in 30.6% of patients over 80 years, and in 12.1% of patients with an ASA score >2; these percentages increased to 45.8% and 19.9% in 2014, respectively. Specificity of MRI for N-stage decreased from 82.9% in 2009 to 62.9% in 2013, with an increase to 73.2% in 2014.
CONCLUSION: The revised national guideline on colorectal cancer was rapidly implemented in the Netherlands with a substantial decrease in RT use for low risk resectable rectal cancer, and increased specificity of MRI for N-staging.
Copyright © 2017 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Clinical auditing; Guideline adherence; Guideline revision; Radiotherapy; Rectal cancer

Mesh:

Year:  2017        PMID: 28351504     DOI: 10.1016/j.ejso.2016.12.019

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  7 in total

1.  Neoadjuvant chemoradiation improves oncologic outcomes in low and mid clinical T3N0 rectal cancers.

Authors:  Olga A Lavryk; Elena Manilich; Michael A Valente; Arshiya Miriam; Emre Gorgun; Matthew F Kalady; Sherief Shawki; Conor P Delaney; Scott R Steele
Journal:  Int J Colorectal Dis       Date:  2019-11-27       Impact factor: 2.571

2.  Emilia-Romagna Surgical Colorectal Cancer Audit (ESCA): a value-based healthcare retro-prospective study to measure and improve the quality of surgical care in colorectal cancer.

Authors:  Ilaria Massa; Federico Ghignone; Giampaolo Ugolini; Giorgio Ercolani; Isacco Montroni; Patrizio Capelli; Gianluca Garulli; Fausto Catena; Andrea Lucchi; Luca Ansaloni; Nicola Gentili; Valentina Danesi; Maria Teresa Montella; Mattia Altini
Journal:  Int J Colorectal Dis       Date:  2022-07-02       Impact factor: 2.796

3.  Security and Radical Assessment in Open, Laparoscopic, Robotic Colorectal Cancer Surgery: A Comparative Study.

Authors:  Shuai-Xi Yang; Zhen-Qiang Sun; Quan-Bo Zhou; Ji-Zhong Xu; Yuan Chang; Kun-Kun Xia; Gui-Xian Wang; Zhen Li; Jun-Min Song; Zhi-Yong Zhang; Wei-Tang Yuan; Jin-Bo Liu
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

4.  Direct inpatient costs and influencing factors for patients with rectal cancer with low anterior resection: a retrospective observational study at a three-tertiary hospital in Beijing, China.

Authors:  Zhishui Chen; Jiahua Leng; Guangying Gao; Lianhai Zhang; Yang Yang
Journal:  BMJ Open       Date:  2018-12-18       Impact factor: 2.692

5.  A Postsurgical Prognostic Nomogram for Locally Advanced Rectosigmoid Cancer to Assist in Patient Selection for Adjuvant Chemotherapy.

Authors:  Chao Zhang; Shutao Zhao; Xudong Wang
Journal:  Front Oncol       Date:  2021-12-24       Impact factor: 6.244

6.  Overstaging: A Challenge in Rectal Cancer Treatment.

Authors:  Jan Scheele; Stefan Andreas Schmidt; Sandra Tenzer; Doris Henne-Bruns; Marko Kornmann
Journal:  Visc Med       Date:  2018-07-31

7.  Effect of understaging on local recurrence of rectal cancer.

Authors:  Louis J X Giesen; Wernard A A Borstlap; Willem A Bemelman; Pieter J Tanis; Cornelis Verhoef; Pim B Olthof
Journal:  J Surg Oncol       Date:  2020-07-11       Impact factor: 2.885

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.